Honest Company Inc vs Vaxcyte Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $557.34M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 18.9× Honest Company Inc's market cap, and Honest Company Inc is more actively traded (749,013 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HNST | PCVX | |
|---|---|---|
Market Cap | $557.34M | $10.51B |
Volume | 749,013 | 2,644,694 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $73.82 |
52-Week Low | $2.10 | $40.32 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $460.95M | $9.14B |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, down 1.74% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.04 EPS versus $0.00926 expected, though revenue declined year-over-year to $371.32M in 2025. Recent news highlights institutional buying from BlackRock and Deutsche Bank, while Seeking Alpha notes the company's turnaround progress through strategic exits and cost reductions.
The stock faces headwinds from negative profitability metrics (-3.56% net margin, -6.87% ROE) and elevated P/E of 48.83, but analyst consensus targets $5.30 with 30% buy ratings. Key risks include continued margin pressure and competitive threats in personal care, while potential upside hinges on sustained operational improvements and market share gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →